[{"id":"7a1267fa-f1d2-4fc1-bf7a-c4921620ad8e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05565378","created_at":"2022-10-04T15:57:49.680Z","updated_at":"2024-07-02T16:35:18.298Z","phase":"Phase 2","brief_title":"A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer","source_id_and_acronym":"NCT05565378","lead_sponsor":"GlaxoSmithKline","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1-H","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1-H"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Jemperli (dostarlimab-gxly) • belrestotug (EOS-448) • nelistotug (GSK6097608)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 10/14/2022","start_date":" 10/14/2022","primary_txt":" Primary completion: 01/17/2025","primary_completion_date":" 01/17/2025","study_txt":" Completion: 01/14/2028","study_completion_date":" 01/14/2028","last_update_posted":"2024-02-21"},{"id":"3564d2f5-0c6d-477b-bf48-60926e198e75","acronym":"","url":"https://clinicaltrials.gov/study/NCT06062420","created_at":"2023-10-02T20:12:29.438Z","updated_at":"2024-07-02T16:35:22.705Z","phase":"Phase 2","brief_title":"Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck","source_id_and_acronym":"NCT06062420","lead_sponsor":"GlaxoSmithKline","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jemperli (dostarlimab-gxly) • nelistotug (GSK6097608)"],"overall_status":"Recruiting","enrollment":" Enrollment 360","initiation":"Initiation: 11/14/2023","start_date":" 11/14/2023","primary_txt":" Primary completion: 09/17/2025","primary_completion_date":" 09/17/2025","study_txt":" Completion: 08/12/2027","study_completion_date":" 08/12/2027","last_update_posted":"2024-01-22"},{"id":"26cd0d05-12f7-423e-81f9-deb6ae30bb87","acronym":"","url":"https://clinicaltrials.gov/study/NCT03739710","created_at":"2021-01-18T18:19:04.366Z","updated_at":"2024-07-02T16:35:44.411Z","phase":"Phase 2","brief_title":"Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT03739710","lead_sponsor":"GlaxoSmithKline","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • docetaxel • Zejula (niraparib) • Jemperli (dostarlimab-gxly) • cobolimab (TSR-022) • feladilimab (GSK3359609) • belrestotug (EOS-448) • nelistotug (GSK6097608)"],"overall_status":"Recruiting","enrollment":" Enrollment 185","initiation":"Initiation: 01/24/2019","start_date":" 01/24/2019","primary_txt":" Primary completion: 07/08/2025","primary_completion_date":" 07/08/2025","study_txt":" Completion: 07/08/2025","study_completion_date":" 07/08/2025","last_update_posted":"2023-06-29"}]